Literature DB >> 27888879

Gray Zone Lymphoma: Current Diagnosis and Treatment Options.

Monika Pilichowska1, Athena Kritharis2, Andrew M Evens3.   

Abstract

The morphology of gray zone lymphoma (GZL) is variable with tumor cells spanning the spectrum of diffuse large B-cell lymphoma (DLBCL) and classical Hodgkin lymphoma. The immunophenotype is frequently discordant. Clinically, the initial case descriptions of GZL were primarily with mediastinal presentation; however, a nonmediastinal (systemic) clinical subtype is now recognized. Patients with GZL have high relapse rates. Recommended treatment of GZL is with a DLBCL-directed regimen with consideration for consolidative radiotherapy for bulk disease. Continued biologic examination of this entity is needed and there should be exploration toward integration of novel targeted therapeutic agents into the treatment paradigm of GZL. Copyright Â
© 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  B-cell; Biology; Classical Hodgkin lymphoma; Diffuse large B-cell lymphoma; Gray zone lymphoma; Prognosis; Treatment

Mesh:

Year:  2016        PMID: 27888879     DOI: 10.1016/j.hoc.2016.07.006

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN: 0889-8588            Impact factor:   3.722


  3 in total

Review 1.  "Do Not Ignore Musculoskeletal Pain"-Initial Presentation of a Rare Malignant Disease: Case Report and Literature Review.

Authors:  Ishan Patel; Arda Akoluk; Vandan Upadhyaya; Shraddhadevi Makadia; Steven Douedi; Taliya Farooq; Daniel Flynn; Michael Levitt; Mohammad A Hossain
Journal:  J Investig Med High Impact Case Rep       Date:  2020 Jan-Dec

2.  A Rare Case of Grey Zone Lymphoma Successfully Treated with Brentuximab Vedotin and R-CHP Chemotherapy.

Authors:  Rajiv M Mallipudi; Lance Alquran; Vishnu A Shenoy; Lori A Leslie; John A Conti
Journal:  Case Rep Oncol Med       Date:  2019-04-11

3.  Transition Between Diffuse Large B-Cell Lymphoma and Classical Hodgkin Lymphoma- Our Histopathological and Clinical Experience With Patients With Intermediate Lymphoma.

Authors:  Zsófia Simon; Bálint Virga; László Pinczés; Gábor Méhes; Zsófia Miltényi; Sándor Barna; Roxana Szabó; Árpád Illés
Journal:  Pathol Oncol Res       Date:  2021-03-30       Impact factor: 3.201

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.